Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy.
Bottom Line: Results of the univariate analysis have been reported previously.The a priori-planned multiple linear regression analysis, which accounted for the effects of disease progression and several other possibly confounding variables on quality of life, showed a significant advantage for epoetin alfa over placebo for the five scales (all, P<0.05), and confirmed the results of the univariate analysis.These findings provide evidence that increasing haemoglobin levels by epoetin alfa administration can significantly improve cancer patients' quality of life.
Affiliation: Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9QG, UK. firstname.lastname@example.orgShow MeSH
Related in: MedlinePlus
Mentions: The multiple linear regression models and parameter values used to generate LSMs for each of the analyses in this report are presented in Table 5Table 5QoL change score multiple linear regression parameter estimates. Table 6Table 6Regression analyses: least squares means, last assessment change scores presents LSM estimates for the seven primary QoL endpoints for the overall analysis and by disease progression status. Results of both the univariate and multiple linear regression analyses of QoL change scores for the two treatment groups are displayed in Figures 4Figure 4
Affiliation: Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9QG, UK. email@example.com